Medeva Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: London United Kingdom (1985)
Status: Acquired by Celltech (1999) → now UCB (2004)

Organization Overview

First Clinical Trial
None
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
None

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 4 Trials (2)

Key: Medeva (0) Acquired (2)

amitriptyline (elavil) (1 trial)

mesalamine (rowasa) (6 trials)

Drugs in Phase 3 Trials (2)

Key: Medeva (0) Acquired (2)

mesalazine (4 trials)

omega-3-carboxylic acids (epanova) (2 trials)

Drugs in Phase 2 Trials (4)

Key: Medeva (0) Acquired (4)

beclomethasone (vanceril) (1 trial)

cefuroxime (zinacef) (1 trial)

guaifenesin (1 trial)

pseudoephedrine (Benylin) (1 trial)

Drugs in Phase 1 Trials (1)

Key: Medeva (0) Acquired (1)

metronidazole (flagyl) (1 trial)

Indications

Overview

  • Highest Phase: None
  • # of Trials: 13
  • # of Trial APIs: 9